Exelixis (EXEL) and Merck (MRK) are both strong in oncology, especially in kidney cancer treatments—Cabometyx for EXEL and Keytruda for MRK. EXEL has outperformed MRK stock so far this year, thanks to product momentum and new approvals, but it's pricier on valuation. MRK has a much more diversified portfolio, a higher dividend yield, and continued growth driven by Keytruda, animal health, and new product launches. While both have a 'Hold' rating, MRK’s diverse pipeline offers a safer long-term pick, especially in volatile markets.